Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.5K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-type-resolved genetic variation shapes inflammatory bowel disease risk.

Nature·2026
Same author

An Alzheimer's disease-associated common regulatory variant in a <i>PTK2B</i> intron alters microglial function.

iScience·2026
Same author

The Human Pleiotropic Map of GWAS Associations and Therapeutic Implications.

bioRxiv : the preprint server for biology·2026
Same author

The Potential of Digital Twins for Pediatric Rare Diseases.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Expression Atlas in 2026: enabling FAIR and open expression data through community collaboration and integration.

Nucleic acids research·2025
Same author

Temporal trends in evidence supporting novel drug target discovery.

Nature communications·2025

Related Experiment Video

Updated: Nov 30, 2025

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

750

Open Targets Platform: supporting systematic drug-target identification and prioritisation.

David Ochoa1,2, Andrew Hercules1,2, Miguel Carmona1,2

  • 1European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.

Nucleic Acids Research
|November 16, 2020
PubMed
Summary

The Open Targets Platform enhances drug discovery by providing updated evidence for target-disease relationships and integrating new genetic and safety data. This improves systematic target identification and prioritization for developing effective and safe medicines.

More Related Videos

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K

Related Experiment Videos

Last Updated: Nov 30, 2025

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

750
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K

Area of Science:

  • * Bioinformatics and Computational Biology
  • * Pharmacology and Drug Discovery

Background:

  • * The Open Targets Platform is a publicly available, open-source knowledgebase for drug target identification and prioritization.
  • * Continuous development is crucial to maintain and improve evidence for target-disease relationships from diverse data sources.

Purpose of the Study:

  • * To describe the latest enhancements to the Open Targets Platform.
  • * To address the challenges of developing effective and safe drugs by improving target identification and prioritization.
  • * To enhance user experience and platform performance.

Main Methods:

  • * Integrated new evidence from genome-wide CRISPR screens (Project Score) and GWAS/UK BioBank data (Open Targets Genetics Portal).
  • * Evolved the evidence scoring framework to refine target identification.
  • * Incorporated post-marketing adverse drug reaction data and curated information on target tractability and safety.

Main Results:

  • * Ten releases have been implemented to update and improve evidence from 20 data sources.
  • * New datasets, including Project Score and Open Targets Genetics Portal, have been integrated.
  • * Enhancements to the evidence scoring, safety, and tractability information aid target prioritization.

Conclusions:

  • * The Open Targets Platform provides an updated, comprehensive resource for drug discovery.
  • * Recent enhancements improve the identification and prioritization of drug targets.
  • * The platform aims to mitigate the difficulty and expense associated with developing effective and safe drugs.